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ABSTRACT		HEPATITIS	C	VIRUS	(HCV)	AND	HUMAN	IMMUNODEFICIENCY	VIRUS	(HIV)	OPT-OUT	TESTING	IN	A	SOUTHERN	FEDERALLY	QUALIFIED	HEALTH	CENTER	(FQHC)		By		LEAH	MICHELLE	PINHOLSTER		APRIL	29,	2019			
INTRODUCTION	The	CDC	recommends	one-time	HCV	screening	of	all	baby	boomers	and	those	at	high	risk	for	infection.	Despite	HCV	being	the	most	common	blood-borne	virus	in	the	US,	routine	HCV	testing	is	not	uniformly	practiced.			
AIM	To	evaluate	the	prevalence	of	HIV/HCV	screening	prior	to	and	following	the	implementation	of	a	dual	routine	opt-out	program,	the	linkage	to	care	practices	for	positive	patients,	and	the	demographic	characteristics	of	positive	patients	in	a	southern	FQHC.		
METHODS	We	conducted	a	retrospective,	cross-sectional	study	using	electronic	health	record	data	from	patients	receiving	care	at	SMC	in	Atlanta.			
RESULTS	Pre-implementation:	Of	the	68	HIV+	patients,	most	were	linked	to	care	(97.05%),	African	American	(95.59%),	non-Hispanic	(98.53%),	and	male	(62.50%).	Of	the	89	HCV+	patients,	most	were	African	American	(67.42%),	non-Hispanic	(97.75%),	male	(53.93%),	and	baby	boomers	(72.02%).	There	were	3	co-infected	patients.	Post-implementation:	Of	the	232	HIV+	patients	most	were	African	American	(82.33%),	non-Hispanic	(93.53%),	and	male	(58.19%).	The	linkage	to	care	rate	was	96.98%.	Of	the	274	HCV+	patients,	52.92%	were	African	American,	94.89%	were	non-Hispanic,	55.84%	were	male,	79.71%	were	linked	to	care,	and	77.38%	were	baby	boomers.	There	were	13	co-infected	patients.		
DISCUSSION	These	results	reflect	the	population	SMC	serves:	non-Hispanic	African	Americans.	The	age	distribution	of	the	HCV+	patients	matched	the	trends	seen	nationwide	for	the	1945-1965	birth	cohort.	There	was	a	286%	increase	for	HIV	tests.	The	increase	in	HIV/HCV	testing	and	high	linkage	to	care	rates	may	partly	be	due	to	the	hiring	of	an	Infectious	Disease	specialist	in	2015.		 						 			
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Chapter	I.	Introduction	This	chapter	will	cover	the	following	topics:	hepatitis	C,	the	similarities	between	HCV	and	HIV	and	the	complications	that	arise	from	co-infections,	an	overview	of	Federally	Qualified	Health	Centers,	opt-out	testing,	HCV	screening,	and	HCV	treatment.	This	will	inform	a	broader	understanding	of	the	need	for	routine	opt-out	testing	in	primary	care	facilities,	the	burden	of	HCV	on	the	healthcare	system,	and	the	emerging	HCV	epidemic	as	a	whole.			Hepatitis	C	Overview	Hepatitis	C	virus	(HCV)	is	a	contagious	infection	that	attacks	the	liver.	It	can	begin	as	an	acute	infection,	but	in	some	instances	the	virus	remains	in	the	body,	resulting	in	chronic	disease	and	long-term	liver	problems.	While	there	are	vaccines	for	other	viruses	in	the	hepatitis	family,	there	is	no	vaccine	for	HCV.1	HCV	is	the	most	common	chronic	blood-borne	pathogen	in	the	US	and	a	leading	cause	of	complications	from	chronic	liver	disease.	Initial	HCV	infection	is	classified	as	an	acute	infection,	often	symptom-less,	which	the	body	can	clear	on	its	own	in	some	cases.	However,	approximately	75-85%	of	those	infected	develop	chronic	infections	due	to	the	virus	remaining	in	the	body.1,2	Chronic	HCV	can	progress	to	chronic	liver	disease,	cirrhosis,	and	hepatocellular	carcinoma.23	Progression	rates	to	these	complications	vary,	with	one	study	approximating	that	10-20%	of	patients	will	develop	cirrhosis	over	20-30.46	For	people	who	develop	cirrhosis,	the	annual	risk	of	HCC	and	hepatic	decompensation	is	1-5%	and	3-6%,	respectively.	Once	hepatic	decompensation	has	occurred,	characterized	by	the	development	of	ascites	and	varices,	a	patient’s	risk	of	death	in	the	subsequent	year	is	between	15-20%.23		HCV	is	primarily	transmitted	when	a	person	is	exposed	to	infected	blood.	Past	or	current	injection	drug	use	(IDU)	is	the	most	common	risk	factor	for	HCV	infection,	with	most	studies	reporting	IDU	as	a	factor	in	more	than	50%	of	cases.10	Other	transmission	pathways	of	HCV	include	needle	stick	injuries	in	the	medical	field,	blood	transfusions,	being	born	to	a	mother	who	has	HCV,	organ	transplants,	hemodialysis,	and	sexual	contact	with	an	infected	person.	The	risk	of	contracting	HCV	from	sexual	contact	with	an	infected	person	increases	for	those	who	have	multiple	sex	partners,	those	who	have	a	sexually	transmitted	disease	(STD),	those	who	engage	in	rough	sex	that	could	cause	bleeding	from	the	penis	or	
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vagina,	and	those	who	are	infected	with	HIV.1	Sharing	items	such	as	razors	or	toothbrushes	and	non-hygienic	practices	with	tattoos	and	piercings	are	less	common	modes	of	transmission.	Before	1992,	HCV	was	most	commonly	spread	through	blood	transfusions	and	organ	transplants	due	to	the	lack	of	blood	screening.	Equipment-related	transmission,	whether	IDU	paraphernalia	or	other,	is	especially	hazardous,	as	the	virus	can	survive	outside	the	body	at	room	temperature,	and	on	environmental	surfaces,	for	up	to	3	weeks.1		Hepatitis	C	Epidemiology		There	are	an	estimated	3.2	million	people	living	in	the	U.S.	that	have	hepatitis	C.1,2,3	About	75%	of	those	affected	are	unaware	of	their	infection.1	Due	to	the	often	symptom-less	nature	and	slow	progression	of	HCV,	those	infected	may	not	be	aware	of	their	infection	until	complications	from	the	disease	have	reached	severe	levels	and	available	treatment	options	have	become	limited.	IDU	is	the	predominant	mode	of	transmission,	and	co-infection	with	HIV	occurs	in	a	significant	amount	of	those	with	HCV.		From	2010-2015,	reported	cases	of	acute	HCV	infection	increased	more	than	2.9-fold,	rising	annually	throughout	this	period.	The	increase	in	acute	HCV	case	reports	reflects	new	infections	associated	with	rising	rates	of	injection-drug	use.	The	increase	may	also	be	due	to	improved	case	detection.1	The	Centers	for	Disease	Control	and	Prevention	(CDC)	estimated	that	in	2015	there	were	33,900	new	HCV	infections.1		For	the	state	of	Georgia	from	2011-2015,	the	reported	rate	of	acute	HCV	cases	ranged	from	0.5	to	0.8	per	100,000	populations.4	These	rates	are	calculated	from	newly	reported	cases	of	either	present	or	confirmed	past	HCV	infection	per	standard	population	of	100,000.		Nationwide,	mortality	among	HCV-infected	persons-primarily	adults	aged	55-64	years	increased	during	2006-2010	and	HCV-associated	deaths	reached	an	all-time	high	of	19,659	in	2014.	A	study	by	Ly	et	al.	found	that	the	annual	HCV-related	mortality	in	2013	surpassed	the	total	combined	number	of	deaths	from	60	other	infectious	diseases	reported	to	CDC.5	These	infectious	diseases	included	HIV,	pneumococcal	disease,	and	tuberculosis.		The	CDC’s	Division	of	Viral	Hepatitis	reports	the	number	of	death	certificates	nationwide	listing	HCV	as	a	cause	of	death	for	each	year	as	part	of	the	HCV	statistics	and	surveillance	system.	An	HCV-related	cause	of	death	is	defined	as	the	primary	cause	of	death	
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or	one	of	the	multiple	causes	of	death	with	the	International	Classification	of	Diseases,	Tenth	Revision,	Clinical	Modification	(ICD-10-CM)	diagnostic	codes	B17.1	and	B18.2	In	2010	the	number	of	death	certificates	was	16,627.	The	number	increased	each	year	and	in	2014	the	total	number	was	19,659.	The	CDC	notes	that	these	numbers	represent	only	a	fraction	of	deaths	that	can	be	attributed	wholly	or	partly	to	chronic	HCV.2	The	majority	of	people	who	died	of	HCV-related	causes	were	aged	55-64	years	old,	were	American	Indian/Alaska	Native,	and	male.		HCV	infection	disproportionately	affects	several	groups	in	regards	to	age,	sex,	race/ethnicity,	and	socioeconomic	status.	Baby	boomers,	those	born	between	1945	and	1965,	males,	people	of	color,	people	who	inject	drugs	(PWID)	and	those	of	a	low	socioeconomic	status	have	higher	rates	of	HCV	infection.	Baby	boomers	represent	75%	of	those	infected.10,11	This	disproportion	may	be	due	to	unsafe	medical	procedures	conducted	in	the	US	in	the	years	after	WWII.15	If	baby	boomers	received	an	injection	or	blood	transfusion	during	this	time,	they	could	have	been	exposed	to	HCV.	Without	a	diagnosis	and	thus	no	treatment,	they	would	have	been	at	an	increased	risk	to	infect	others.	Men	have	higher	rates	of	chronic	HCV	than	women.	Baden	et	al	found	that	women	have	a	higher	chance	of	spontaneously	clearing	HCV	and	those	who	do	not	clear	the	infection	have	a	slower	progression	to	liver	disease.44	A	study	by	Franco	et	al	found	that	men	were	less	likely	to	utilize	healthcare	and	more	likely	to	partake	in	unhealthy	behaviors,	like	smoking	and	alcohol	abuse.	Men	were	also	found	to	be	less	likely	to	participate	in	preventative	care	and	to	view	disease	risk	as	less	severe	than	women.11		Studies	have	shown	that	minorities	have	higher	HCV	prevalence.	A	study	by	Coyle	et	al	found	that	there	were	more	non-Hispanic	black	patients	with	current	HCV	infection	than	any	other	racial/ethnic	group.12	Between	September	and	December	2009,	a	sample	of	466	IDU	in	metropolitan	Atlanta	was	surveyed	to	monitor	behaviors	associated	with	transmission	of	HIV.13	The	African	American	PWID	had	the	highest	percentages	of	both	HIV	and	HCV.	These	survey	results	show	the	extent	that	these	infections	disproportionately	affect	different	races.	The	Office	of	HIV/AIDS	and	Infectious	Disease	Policy	released	a	compilation	of	facts	focusing	on	HCV	and	African	Americans	in	2015.45	Data	from	the	National	Health	and	Nutrition	Examination	Survey	(NHANES)	showed	that	between	1999	
	 4	
and	2002,	African	Americans	had	a	prevalence	rate	of	HCV	that	was	more	than	twice	that	found	in	non-Hispanic	whites.	This	increased	rate	may	be	due	to	higher	rates	of	sickle	cell	disease	and	the	subsequent	need	for	blood	transfusions	during	a	time	when	blood	screening	was	not	as	rigorous	as	it	is	today.	In	addition	to	infection	rates,	African	Americans	also	have	the	highest	rates	of	mortality	from	HCV.45		In	recent	years,	a	new	wave	of	acute	HCV	cases	has	been	developing	in	people	who	inject	drugs.15	Young,	white	people	living	in	rural	and	suburban	parts	of	the	Midwest	and	Eastern	US	with	a	history	of	IDU	were	the	predominant	demographic	of	these	new	infections.	This	increasing	population	of	young	PWID	has	led	to	a	doubling	of	reported	acute	cases	since	2010.		Those	who	are	uninsured	or	underinsured	are	also	disproportionately	affected	by	HCV.11	Additionally,	those	who	live	in	households	with	annual	incomes	<$25,000,	have	a	history	of	incarceration,	are	homeless,	or	are	poorly	educated	show	higher	HCV	prevalence	than	those	who	live	in	households	with	greater	annual	incomes,	those	without	a	history	of	incarceration,	those	who	have	stable	housing,	and	those	who	are	educated.8	These	populations	of	low	socioeconomic	status	are	also	more	likely	to	engage	in	risky	behaviors	such	as	drug	use	and	less	likely	to	have	access	to	health	care	due	to	disproportionate	placement	of	medical	facilities.8	HCV	does	not	occur	evenly	throughout	the	various	geographic	regions	of	the	US.	A	2017	study	by	Rosenberg	et	al.,	found	that	HCV	infection	has	most	impacted	the	western	and	southern	regions	of	the	US,	with	the	west	having	the	highest	region-specific	prevalence	(2.14%),	and	the	South	having	the	highest	number	of	persons	testing	positive	for	the	presence	of	HCV	antibodies	(n=1561600).18		Hepatitis	C	Virus	(HCV)	Burden	The	increasing	number	of	people	in	the	US	who	are	living	with	HCV,	coupled	with	75%	of	those	infected	being	undiagnosed	and	unaware	of	their	infection,	puts	a	considerable	burden	on	the	healthcare	system	and	on	healthcare	spending.	If	diagnosed	early,	patients	can	utilize	treatments	that	are	highly	effective	for	the	majority	of	infections	and	last	two	to	three	months.6	Acute	HCV	infection	can	be	symptom-less	but	some	people	experience	fever,	fatigue,	dark	urine,	clay-colored	bowel	movements,	abdominal	pain,	joint	
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pain,	nausea	and	vomiting.	However,	when	those	infected	do	seek	treatment	it	is	often	once	the	infection	has	become	severe	enough	to	indicate	that	there	has	been	damage	to	the	liver.	At	that	point,	the	treatment	options	for	severe	liver-related	conditions	are	limited	and	those	that	are	available	are	costlier	and	more	intensive	than	interventions	used	to	treat	acute	HCV	infection.		One	of	the	groups	at	highest	risk	of	HCV	is	the	baby	boomer	population,	those	born	between	1945	and	1965.	As	this	population	ages,	HCV-associated	morbidity	and	mortality	rates	are	projected	to	increase	over	the	next	few	decades.7	This	includes	new	cases	of	cirrhosis	from	HCV	(by	over	30%	as	of	2020),	HCC,	liver	de-compensation,	and	liver-related	deaths.3	Currently	annual	direct	costs	are	estimated	to	be	$1.1	billion,	and	indirect	costs	are	estimated	to	be	$7.5	billion.	Because	so	many	infected	people	do	not	know	they	are	infected,	annual	direct	spending	is	expected	to	exceed	$10.7	billion	between	2010-2019.7	HCV	and	its	associated	complications	have	a	significant	impact	on	healthcare	resource	utilization	and	costs.		HIV/HCV	Comorbidity	and	Epidemiology	HCV	and	HIV	have	many	epidemiological	similarities	including	risk	factors,	transmission	routes,	and	disproportionately	affected	groups.	Deaths	due	to	HCV	have	exceeded	deaths	related	to	HIV/AIDS	nationally	since	2007.1,2	Although	HCV	is	a	considerable	burden	on	the	healthcare	sector,	funding	for	HCV	prevention	and	research	continues	to	be	less	than	funding	for	HIV	efforts.	In	the	2017	FY	request,	$39	million	was	proposed	for	viral	hepatitis	as	part	of	CDC’s	HIV/AIDS,	viral	hepatitis,	STI,	and	TB	prevention	programs,	compared	to	$788	million	for	domestic	HIV/AIDS	prevention	and	research.19	An	estimated	20%	of	those	infected	with	HIV	are	co-infected	with	HCV.12	For	people	with	HCV/HIV	co-infection,	the	chance	of	liver-related	morbidity	and	mortality	is	higher,	even	when	the	HIV	infection	is	well	controlled.22	Continued	effort	for	these	federally	funded	programs	is	needed	as	the	incidence	of	hepatocellular	carcinoma	increases	in	HIV	co-infected	patients.	Co-infected	patients	account	for	93%	of	hepatocellular	carcinoma	cases	and	studies	have	reported	a	10-fold	increase	in	mortality	for	these	patients.	Antiretroviral	therapy	and	HCV	therapies	benefit	co-infected	patients	and	improve	
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prognosis.23	In	2016,	Platt	et	al.	conducted	a	systematic	review	and	meta-analysis	on	studies	that	reported	on	HCV	and	HIV	co-infection.	The	prevalence	of	HIV-HCV	co-infection	was	found	to	be	2.4%	in	the	general	population,	4.0%	in	the	pregnant	population,	4.0%	in	the	heterosexual	population,	6.4%	in	men	who	have	sex	with	men	(MSM),	and	82.4%	in	PWID.	People	living	with	HIV	were	six	times	more	likely	to	have	HCV	co-infection	when	compared	to	their	HIV-negative	counterparts.15	In	patients	with	HIV,	the	progression	to	cirrhosis	is	more	rapid	than	in	mono-infected	patients.	In	the	US,	about	20%	of	HIV-infected	patients	are	also	co-infected	with	HCV.	Across	the	world,	patients	with	HIV	are	6	times	more	likely	to	be	infected	with	HCV	than	the	general	population.	PWID	are	most	likely	to	have	co-infection,	and	in	the	US,	50%	to	90%	of	HIV-infected	PWID	are	also	co-infected	with	HCV.24	Co-infection	results	in	accelerated	liver	fibrosis,	higher	HCV	loads,	and	poorer	responses	to	interferon-based	therapy	when	compared	with	HCV	mono-infection.	In	the	absence	of	HIV,	about	25%	of	those	infected	will	spontaneously	clear	HCV	infection.25	The	rest	will	have	persistent	infection	marked	by	ongoing	viremia,	a	virus	being	present	in	the	bloodstream.	In	HIV	co-infection,	the	rate	of	spontaneous	clearance	ranges	from	5-24%.	In	co-infection,	the	viral	set	point	is	increased	in	HIV	infection	with	an	HCV	load	more	than	1	log	higher	than	those	who	are	HCV	mono-infected.	In	chronic	HCV	infection,	HIV-positive	men	are	more	likely	to	shed	HCV	RNA	in	semen	than	their	HIV-negative	counterparts.	Some	have	suggested	screening	high-risk	populations	with	HCV-RNA	testing,	as	the	humoral	response	to	HCV	appears	to	be	delayed	in	HIV	infection.43	As	HIV-related	mortality	and	morbidity	have	declined,	HCV-related	liver	disease	has	increased.	The	availability	of	highly	active	antiretroviral	therapy	(HAART)	has	improved	outcomes	for	those	infected	with	HIV,	however	HIV/HCV	co-infected	patients	continue	to	face	hurdles	in	the	treatment	of	their	infections.	HAART	can	lead	to	a	decline	in	HCV	liver-related	mortality,	but	it	can	also	increase	risk	of	hepatotoxicity.	Combining	other	drugs,	such	as	pegylated	interferon	with	ribavirin,	has	led	to	improved	treatment	outcomes;	however,	HIV	continues	to	accelerate	HCV	liver-related	conditions.26		Funding	efforts	for	the	treatment	and	prevention	of	HIV	have	had	great	success	in	combating	the	HIV	epidemic.	Due	to	the	similarities	between	HIV	and	HCV	and	the	rates	of	
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comorbidity	between	the	two	infections,	the	model	used	to	promote	funding	that	addressed	the	HIV	epidemic	could	also	be	used	to	address	the	emerging	HCV	epidemic.	HCV-targeted	funding	would	improve	the	lives	of	those	living	with	HCV	infection,	as	well	as	those	at	risk	and	those	with	HIV	co-infection.		Federally	Qualified	Health	Centers	Federally	Qualified	Health	Centers	(FQHC)	are	an	important	part	of	healthcare,	especially	for	those	who	are	underserved	and	uninsured.	FQHCs	provide	primary	and	preventive	care	including	health	services,	oral	health	services,	mental	health	services,	and	substance	abuse	services	to	anyone,	irrespective	of	their	insurance	status.	FQHCs	are	community	health	centers	that	are	reimbursed	by	the	Bureau	of	Primary	Health	Care	and	the	Centers	for	Medicare	and	Medicaid	Services	of	the	US	Department	of	Health	and	Human	Services.32		In	many	areas	of	the	south,	community	health	centers	are	key	players	in	the	healthcare	system	and	community	health	centers	like	Southside	Medical	Center	provide	care	and	support	to	communities	that	are	underserved	in	healthcare;	communities	who	also	are	most	burdened	by	diseases	such	as	HIV	and	HCV.33	Southside	Medical	Center	(SMC)	was	founded	in	1967	in	southeast	Atlanta	and	is	one	of	Atlanta’s	largest	FQHCs.	A	private,	non-profit	FQHC,	SMC’s	mission	is	to	serve	the	medically	underserved	and	impoverished	communities	in	metropolitan	Atlanta.33	The	population	around	Southside	consists	of	high	rates	of	no	insurance	(16%)	and	poverty	(24%	of	the	population	live	below	200%	of	the	federal	poverty	level).34	Southside’s	client	population	is	overrepresented	in	these	aspects,	56%	lack	health	insurance	and	56%	live	below	200%	of	the	federal	poverty	level.	Southside	Medical	Center	has	11	clinic	sites	in	and	around	the	Atlanta	area.	Clinics	are	located	in	the	following	counties:	Fulton	(4),	Clayton	(2),	Henry	(2),	Butts	(1),	DeKalb	(1),	and	Spalding	(1).	Southside	serves	over	30,000	patients	each	year.	The	majority	of	these	patients	are	black	(89%),	female	(68%),	living	below	200%	of	the	federal	poverty	level	(56%),	and	uninsured	(56%).33	SMC	has	a	unique	position	in	the	community	in	that	it	provides	comprehensive	care	to	all	patients	in	both	urban	and	rural	settings,	regardless	of	insurance	status.	This	comprehensive	care	includes	adult	medicine,	pediatrics,	OBGYN,	dentistry,	optometry,	
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podiatry,	mental	health	and	substance	abuse	treatment,	infectious	disease,	and	an	onsite	pharmacy.	Patients	benefit	from	multiple	specialties	being	housed	in	one	site.	In	June	2012,	routine,	opt-out	HIV	screening	was	implemented	for	all	patients	13-64	years	of	age.	Prior	to	this,	routine	screening	was	performed	in	the	women’s	health	clinic	and	at	the	behavioral	health	clinic.33	In	the	12	months	prior	to	the	start	of	the	routine	program,	812	patients	were	screened	and	1.6%	of	those	tested	were	HIV	positive.	21%	of	eligible	patients	were	screened	for	HIV	from	May	2013-April	2014.	During	this	time,	0.7%	of	those	screened	were	HIV	positive	and	99%	were	linked	to	care	within	90	days	of	diagnosis.	In	the	most	recent	12	months	of	the	screening	program	there	were	6767	HIV	tests	conducted,	44	(0.7%)	of	which	were	positive.	Routine	HCV	opt-out	testing	began	two	years	later	in	March	of	2014.	Routine	HIV/HCV	opt-out	testing	at	SMC	was	funded	by	Gilead’s	FOCUS	Program.		The	burden	of	HCV	is	clear;	however,	routine	HCV	screening	is	not	implemented	nationwide.	Even	when	HCV	and	HIV	testing	occurs,	the	decision	to	test	is	mostly	based	on	a	patient’s	risk	level,	despite	the	CDC’s	2012	recommendations.12	Due	to	the	similarities	of	both	infections,	dual	HCV/HIV	opt-out	screening	is	one	way	to	relieve	some	of	the	burden	of	these	diseases.	This	study	of	Southside	Medical	Center’s	dual	HIV/HCV	opt-out	testing	aims	to	measure	the	impact	of	increased	screening	measures	on	patient	health	outcomes.			HCV	Screening	Screening	and	early	detection	are	not	only	beneficial	for	patients,	but	are	also	cost-effective	long-term.	If	screening	were	implemented	broadly,	the	complications	of	HCV	could	decrease	by	16-42%.3		Furthermore,	identification	of	HCV	infection	before	the	onset	of	long-term	complications	is	shown	to	be	cost	effective	and	prevents	transmission	of	HCV.8,9	Despite	HCV	being	the	most	common	blood-borne	virus	in	the	US	and	the	substantial	scale	and	burden	of	the	disease,	routine	HCV	testing	is	not	uniformly	practiced.7	Screening	for	HCV	leads	to	early	diagnosis	and	thus	earlier	access	to	treatment,	more	treatment	options	of	a	chronic	infection,	prevents	the	development	of	HCV-related	complications.27	Implementation	of	screening	programs	leads	to	reduced	mortality	and	improved	outcomes	overall.9	Screening	strategies	include	opt-out	universal	screening,	opt-in	testing,	and	risk-based	testing.	Choice	of	a	testing	strategy	is	likely	influenced	by	the	
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perception	of	disease	prevalence	and	budget	limitations.27	For	diseases	that	are	considered	rare,	risk-based	testing	would	be	less	costly	than	opt-out	testing	due	to	the	small	number	of	cases	in	a	population.		There	are	two	tests	used	to	detect	HCV,	an	antibody	test	and	a	confirmatory	test.	The	antibody	test	(anti-HCV	or	HCV	Ab)	detects	HCV	antibodies	present	in	a	patient’s	blood,	which	indicates	the	person	has	been	exposed	to	HCV	but	hasn’t	necessarily	developed	a	chronic	infection.	The	confirmatory	test	detects	the	presence	of	HCV	ribonucleic	acid	(RNA),	which	conclusively	identifies	those	actively	infected.7	An	estimated	30%	of	those	testing	anti	HCV+	never	receive	an	HCV	RNA	test	to	confirm	current	infection.	This	leaves	them	undiagnosed	for	chronic	infection.40	The	U.S.	Preventative	Services	Task	Force	(USPSTF)	has	determined	that	an	anti-HCV	antibody	test	and	subsequent	RNA	test	accurately	detects	chronic	HCV	infection.10		HCV	Treatment	Treatment	for	chronic	HCV	infection	entails	regular	medical	assessments	by	a	primary	care	provider,	and	can	involve	specialists	such	as	a	hepatologist,	gastroenterologist,	oncologist,	infectious	disease	specialist,	and	a	primary	care	provider.7		Treatment	of	HCV	has	changed	greatly	since	the	first	treatment,	interferon,	was	approved	by	the	FDA	in	1991.	Interferon	injections	boosted	the	immune	system,	rather	than	targeting	the	virus.	The	cure	rate	was	6%.	A	combination	of	interferon	injections	and	ribavirin	pills	were	used	in	the	following	years,	and	cure	rates	were	about	50%.	Treatment	duration	could	last	for	a	year,	and	side	effects	resembled	those	from	chemotherapy.	In	2011,	cure	rates	increased	to	70%	when	protease	inhibitors,	antiviral	agents,	were	combined	with	interferon	and	ribavirin.	Since	2013,	the	cure	rate	has	exceeded	90%	due	to	new	antiviral	agents.	These	new	therapies	consist	of	one-pill	regimens	and	3-pill	regimens	and	are	taken	for	8-24	weeks.	These	medications	have	fewer	side	effects,	are	easy	to	take,	and	have	an	increased	chance	of	cure	for	those	who	take	them	as	prescribed.28,29		For	those	with	an	HIV/HCV	co-infection,	a	specialist	who	has	the	expertise	to	select	HIV	and	HCV	therapies	that	do	not	have	interactions	will	be	needed.24	People	with	chronic	infection	may	also	require	continual	access	to	a	pharmacy,	help	with	medical	insurance	issues,	and	emotional	and	psychological	support,	linkage-to-care	coordinator,	counselor,	
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on-site	social	worker,	certified	application	counselor	to	complete	the	insurance	process,	and	a	bridge	counselor	or	patient	navigator.11	Thus,	a	fundamental	aspect	of	continuing	treatment	is	linkage	to	care.	When	a	patient	is	linked	to	care,	he/she	is	provided	access	to	these	many	facets	of	continued	treatment,	which	increases	the	likelihood	of	better	health	outcomes.		Linkage	to	care	does	not	have	a	universal	definition.	Generally,	linkage	to	care	is	defined	as	attendance	of	a	medical	visit	following	a	diagnosis	within	a	specific	time	frame.30	Linkage	to	care	often	falters,	as	it	relies	on	infected	individuals	to	be	diagnosed,	to	be	made	aware	of	and	have	an	understanding	of	their	diagnosis,	and	to	have	access	to	care	continuously	over	a	period	of	time.	There	are	several	barriers	to	successful	linkage	to	care	because	of	the	patient	population	and	the	natural	progression	of	the	disease.	Franco	et	al	found	that	substance	abuse	and	psychiatric	disease	were	prevalent	in	the	cohort	(37%	and	30%,	respectively)	and	that	substance	abuse	was	associated	with	LTC	failure	((OR,	1.91;	95%	CI,	1.17–3.11;	P	=	.01).	Moreover,	the	strongest	independent	predictor	of	LTC	failure	was	lack	of	insurance.	These	barriers	have	a	significant	impact	on	LTC,	as	it	is	estimated	that	more	than	60%	of	individuals	who	have	received	a	diagnosis	are	not	engaged	in	care.11	Opt-Out	Testing	Opt-out	testing	occurs	after	a	patient	is	notified	that	the	test	will	be	done.	The	test	is	carried	out	unless	the	patient	refuses	consent.	Opt-in	testing	requires	patients	to	specifically	ask	their	healthcare	provider	to	have	the	test.	In	2006,	the	CDC	gave	the	recommendation	that	opt-out	testing	for	HIV	should	be	implemented	for	the	general	population.3	In	2012,	the	CDC	revised	HCV	screening	recommendations	to	include	one-time	testing	of	all	baby	boomers	and	screening	for	those	who	are	at	high	risk	for	infection	(outlined	above).11	A	downside	of	risk-based	screening	is	that	risk	assessment	is	largely	based	on	self-reported	factors	and	thus	reliant	on	a	patient’s	cooperation	and	honesty.	Patient	reluctance	to	disclose	risk	behaviors	and	sensitive	information	can	diminish	the	ability	to	reliably	assess	risk	and	can	lead	to	a	gap	in	risk	behavior	detection.8	Because	risk-based	screening	uses	self-reported	risk	as	a	proxy	for	prevalence,	it	is	difficult	to	accurately	identify	all	modes	of	transmission.	In	facilities	that	utilize	risk-based	testing,	reliance	on	self-reported	risk	factors	is	shown	to	limit	case	
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finding.8	Another	downside	to	risk-based	testing	is	that	up	to	45%	of	those	infected	do	not	know	how	they	contracted	virus.7		Routine	testing	at	a	primary	care	setting	offers	many	benefits,	however	it	is	not	commonly	integrated	into	primary	care.	Primary	care	facilities	are	able	to	utilize	reflex	laboratory-based	testing	as	well	as	support	services	necessary	for	patients	to	move	from	primary	care	to	HCV	care.	Furthermore,	a	primary	care	provider	known	to	and	trusted	by	the	patient	can	disclose	test	results	as	well	as	provide	support	and	assist	with	the	patient’s	treatment.7		Per	the	CDC’s	recommendations,	a	comprehensive	prevention	program	incorporates	testing	for	HCV,	HCB,	and	HIV	and	rapidly	links	positive	patients	with	appropriate	medical	care.	For	drug-related	HCV	positive	patients	access	to	substance	abuse	treatment	as	well	as	needle	exchange	programs	will	be	needed.6	A	2014	study	assessed	the	perspectives	of	primary	care	providers	concerning	HCV	testing.31	The	providers	who	had	not	implemented	the	CDC’s	recommendations	cited	the	increased	amount	of	time	needed	to	assess	the	patient’s	risk-factor	history	and	to	discuss	sensitive,	stigmatized	behaviors.	These	providers	were	also	concerned	that	health	insurance	would	not	completely	cover	HCV	testing	and	treatment,	and	that	patients	would	not	receive	the	appropriate	support	needed	for	treatment.					 	
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Chapter	II.	Literature	Review		Of	the	available	literature	examining	the	implementation	of	HCV	screening	programs,	only	a	few	were	focused	on	the	efforts	of	primary	healthcare	settings	and	federally	qualified	health	centers.	Other	available	literature	examined	HCV	testing	in	emergency	departments	or	prisons	and	jails.	While	these	models	yield	valuable	information,	the	methods	and	diagnostic	standards	are	not	comparable	to	community	healthcare	settings.	There	continues	to	be	a	need	for	in-depth	research	into	routine	opt-out	testing	in	primary	care.		A	2016	study	by	Crumby	et	al.	examined	SMC	and	another	FQHC	in	the	south,	Central	Care	in	Houston,	Texas.	Like	SMC,	Central	Care	also	implemented	a	comprehensive	program	for	routine	HIV	screening	and	linkage	to	HIV	care.	The	study	reviewed	medical	record	data	to	analyze	patient-level	health	outcomes,	the	number	of	HIV	screening	performed,	the	number	of	positive	HIV	tests,	and	successful	linkage	to	care	for	the	12	months	before	and	after	the	start	of	the	programs.33	The	results	showed	that	out	of	the	52,437	eligible	patients	at	SMC,	80%	were	offered	an	HIV	test	and	27%	of	those	were	tested.	Among	those	screened,	0.7%	were	positive.	Ninety	nine	percent	of	patients	testing	HIV	positive	were	linked	to	care	within	90	days.	Compared	to	the	12	months	prior	to	the	start	of	the	program,	there	was	a	733%	increase	in	conducted	HIV	tests,	and	a	238%	increase	in	patients	who	tested	positive.	The	majority	of	patients	who	received	an	HIV	test	were	female,	aged	23-40	years,	non-Hispanic,	and	black.	The	majority	of	patients	who	tested	positive	for	HIV	at	Southside	were	male,	aged	31-50	years,	non-Hispanic,	and	black.		Of	the	22,658	eligible	patients	at	Central	Care,	48%	were	offered	an	HIV	test	and	91%	of	those	were	tested.	Among	those	screened,	0.5%	were	positive.	Seventy	nine	percent	of	those	testing	HIV	positive	were	linked	to	care.	Compared	to	prior	to	the	start	of	the	program,	there	was	a	618%	increase	in	conducted	HIV	tests,	and	a	600%	increase	in	patients	who	tested	positive.	Non-Hispanic	black	females	between	the	ages	of	13-30	years	represented	the	majority	of	the	screened	patients.	The	majority	of	those	testing	positive	for	HIV	were	black	males	aged	41-50	years.	This	study	demonstrated	the	effectiveness	of	implementation	of	routine	HIV	screening	programs	that	can	dramatically	increase	testing	volume	and	linkage	to	care.	This	model	is	beneficial	to	other	community	health	centers	
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considering	routine	opt-out	testing	for	HIV,	as	well	as	any	primary	care	center	interested	in	beginning	other	screening	programs.		Two	2016	studies	by	Coyle	et	al.	aimed	to	increase	rates	of	HCV	testing,	disease	detection,	and	linkage	to	care	in	FQHCs	in	Philadelphia,	Pennsylvania.	7,12	The	first	study	incorporated	a	routine	HCV	testing	model	into	primary	care	at	five	FQHCs	and	assessed	the	effects	of	the	model	on	testing	rates,	case	identification,	and	linkage	to	care.	From	October	1,	2012	to	June	30,	2014,	an	integrated	HCV	opt-out	testing	model	was	implemented	at	five	primary	health	care	centers,	two	of	which	specialize	in	treating	HIV	patients	and	HCV	patients,	using	several	strategies:	modification	of	electronic	health	records,	revision	of	clinic	policies,	and	education	of	staff	members	on	topics	such	as	HCV	etiology	and	epidemiology.	A	medical	assistant	initiated	the	opt-out	testing	program	for	each	patient,	which	was	followed	by	laboratory-based	testing	supported	by	grant-funded	laboratories	for	patients	without	insurance.	Staff	members	were	trained	in	regards	to	the	shared	EHR,	project	goals,	and	the	overall	plan	for	the	model.	In	order	to	determine	the	more	efficient	testing	method,	the	two	health	centers	specializing	in	high-risk	populations	implemented	a	universal	testing	program,	and	the	three	health	centers	providing	general	primary	care	implanted	a	risk-based	testing	program.	Patients	with	risk	factors	included:	those	born	between	1945	and	1965;	those	with	a	history	of	intranasal	or	IDU;	recipients	of	a	tattoo	or	piercing	from	an	unlicensed	location;	recipients	of	a	blood	transfusion/organ	transplant	before	1994;	women	who	had	a	cesarean	section	before	1990;	HIV-positive	patients	without	an	HCV	test	in	their	medical	chart;	those	on	long-term	hemodialysis,	those	with	a	liver	condition,	those	with	work-related	exposure	to	infected	blood,	and	those	who	are	ever-homeless.	HCV	AB	testing	was	provided	to	4,207,	with	11.6%	testing	anti-HCV	positive.	Of	those	testing	antibody	positive,	88.7%	received	a	confirmatory	HCV	RNA	test	and	72.3%	of	these	had	a	current	HCV	infection	(overall	prevalence=7.4%).	HCV	RNA-positive	patients	were	further	broken	down	into	three	categories:	received	HCV	RNA-positive	results	(77.6%),	referred	to	an	HCV	provider	(58.8%),	and	successfully	linked	to	care	(38.7%).	The	results	of	this	study	illustrate	the	effectiveness	of	routine	testing,	whether	risk-based	or	universal,	in	FQHCs	to	identify	people	having	never	received	an	HCV	test,	those	currently	HCV	positive,	providing	awareness	of	their	current	HCV	status	and	linking	HCV-positive	patients	to	care.	This	model	provides	a	template	for	other	primary	
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care	or	community	health	care	centers	in	integrating	HCV	testing	and	linkage	to	care,	as	well	as	identifying	potential	barriers	faced	in	implementation	of	a	similar	program.	The	second	study	conducted	by	Coyle	et	al.	built	upon	the	already-implemented	HCV	testing	model	from	the	previous	study	and	incorporated	routine	HIV	opt-out	testing	in	four	of	the	five	Philadelphia	FQHCs.	This	study	aimed	to	examine	how	a	dual-routine	HCV/HIV	testing	model	impacts	community	health	centers	in	terms	of	viability	of	program	implementation,	screening	rates,	case	identification,	and	successful	linkage	to	care.12	The	dual-routine	HCV/HIV	testing	model	was	defined	as:	an	opt-out	HCV	test	for	high-risk	patients	coupled	with	an	opt-out	non-risk-based	HIV	test	for	all	patients.12	Comparisons	were	made	between	the	9-month	period	with	the	routine	HCV	testing	model	and	opt-in	HIV	testing,	and	the	9-month	period	with	the	routine	HCV	testing	model	and	opt-out	HIV	testing.		The	success	of	this	dual-routine	testing	program	in	increasing	HCV	and	HIV	screening,	improved	case	identification,	and	enhanced	linkage	to	care	shows	that	similar	testing	programs	implemented	in	the	primary	care	setting	are	feasible	and	yield	positive	results.	Because	HCV	and	HIV	disproportionately	affect	poor	and	minority	populations,	community	health	centers	that	serve	these	populations	could	benefit	greatly	from	this	testing	model.	The	testing	model	incorporated	a	multi-faceted	strategy	that	included	staff	training	sessions,	system-wide	health-care	modifications	for	opt-out	testing	and	laboratory	requisitions,	and	changes	to	the	EMR	system	such	as	daily	queries	in	charts	and	reports	used	to	track	patients.			The	results	from	the	second	study	by	Coyle	et	al.	showed	that	the	amount	of	tests	given,	the	number	of	new	diagnoses,	and	linkage	to	care	increased	during	the	dual-routine	HCV/HIV	testing	model	implementation	compared	to	the	routine	HCV	testing	and	HIV	opt-in	testing	model.	Dual-routine	HCV/HIV	testing	resulted	in	a	23.7%	increase	in	HCV	tests	and	a	124.7%	increase	in	HIV	tests,	a	44.3%	increase	in	HCV	case	identification	using	HCV	RNA	tests,	a	225.0%	increase	in	HIV	case	identification,	an	increase	in	the	percentage	of	HCV	patients	linked	to	care	from	49.1%	to	66.1%,	and	an	increase	in	the	number	of	HIV	patients	linked	to	care	from	1	to	9.		Evaluation	of	opt-out	testing	for	HCV	is	not	represented	in	the	current	literature.	Studies	in	FQHCs	focus	on	screening	practices	already	in	place,	increasing	linkage	to	care	
	 15	
efforts,	and	educating	staff.	In	2015,	several	FQHCs	in	urban	Alameda	County,	California,	developed	an	initiative	to	expand	hepatitis	C	treatment	into	primary	care.35	The	four	FQHCs	collaborated	to	build	a	program	that	educated	staff,	increased	capacity,	discussed	best	practices,	and	facilitated	training.	The	project	measured	HCV	testing	and	linkage	to	care	data.	During	the	measurement	period	of	16	months,	the	number	of	patients	who	began	HCV	treatment	increased	by	538%.	Of	these	patients,	96%	have	been	cured.	This	capacity	building	initiative	demonstrated	how	developing	a	site-wide	program	that	educations,	trains,	and	fosters	collaboration	among	community	organizations	can	expand	access	to	treatment.		There	were	several	studies	available	in	the	literature	that	examined	multiple	clinical	settings.	While	these	studies	did	not	focus	solely	on	community	health	centers	or	FQHCs,	they	are	still	of	value	in	assessing	routine	opt-out	testing	across	a	wide	range	of	healthcare	sites.	A	study	by	Patel	et	al.	examined	several	US	sites	to	assess	HCV	birth-cohort	testing	and	linkage	to	care	from	2012-2014.37	The	104	different	clinical	sites	were	comprised	of	emergency	departments,	FQHCs,	community	health	clinics,	STD	clinics,	and	state	health	departments	in	cities	in	California,	Colorado,	Georgia,	New	York,	North	Carolina,	Pennsylvania,	Puerto	Rico,	South	Carolina,	Texas,	and	Washington,	D.C.	The	testing	population	was	previously	undiagnosed	people	from	the	birth	cohort,	as	well	as	those	who	reported	HCV	risk	factors	in	accordance	to	the	CDC	recommendations.	Three	groups	were	analyzed	according	to	their	testing	and	results	status:	those	who	were	anti-HCV	positive,	those	tested	for	HCV	RNA,	and	those	who	were	HCV	RNA	positive.	Demographic	data	and	reported	risk	factors	were	included	in	the	analysis.		A	total	of	24,966	participants	received	Ab	HCV	testing.	Groups	with	the	highest	frequency	of	testing	were:	those	born	between	1961	and	1965,	those	who	were	non-Hispanic	black,	and	women.	Of	those	tested,	11.6%	were	Ab	HCV	positive.	Of	the	2,900	people	testing	Ab	HCV	positive,	2,108	(72.7%)	received	testing	for	HCV	RNA.	A	total	of	1,497	people	tested	positive	for	HCV	RNA	and	938	were	successfully	linked	to	care.	This	study	showed	that	birth-cohort	testing	could	be	successful	in	different	healthcare	settings.	For	successful	and	impactful	engagement	in	the	HCV	care	cascade,	primary	care	facilities	must	champion	testing	initiatives	and	linkage	to	care.	The	established	HIV	care	continuum	can	serve	as	a	model	for	developing	a	care	continuum	for	HCV.	A	2016	study	by	Seña	et	al.	used	this	strategy	to	implement	an	HCV	
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testing	and	linkage	to	care	program	through	the	Durham	County	Department	of	Public	Health	from	December	2012-February	2014.38	HCV	Ab	testing	with	reflex	RNA	was	offered	through	a	sexually	transmitted	disease	clinic,	a	county	jail,	community	testing	sites	(including	a	residential	substance	abuse	recovery	program),	and	a	homeless	clinic.	Positive	patients	were	linked	to	care	through	an	HCV	bridge	counselor	who	provided	education,	incentives,	and	transportation,	and	scheduled	appointments	with	HCV	specialists	at	nearby	academic	centers	and	on-site	clinics.	The	study	defined	linkage	to	care	for	HCV	using	the	definitions	from	the	HIV	care	continuum:	The	process	of	assisting	people	diagnosed	with	chronic	HCV	infection	with	their	initial	visits	with	an	HCV	medical	provider.	The	established	provider	networks	and	existing	funding	programs	of	HIV	can	facilitate	similar	networks	and	a	coordinated	system	of	care	for	HCV.	In	addition	to	showing	the	benefits	of	basing	an	HCV	program	on	an	already-established	HIV	program,	the	study	found	the	following	demographic	trends:	among	those	with	current	infection	(241	people),	73.9%	were	men,	55.2%	were	born	between	1945-1965,	62.2%	reported	ever	injecting	drugs,	2.5%	were	co-infected	with	HIV,	and	51%	were	linked	to	care.		In	October	2012,	the	Grady	Memorial	Hospital	Primary	Care	Center	and	Grady	Liver	Clinic	in	Atlanta,	Georgia	began	the	Internal	Medicine	Trainees	Identifying	and	Linking	to	Treatment	for	Hepatitis	C	(TILT-C).	TILT-C	aimed	to	conduct	routine	HCV	screening	with	the	goal	of	identifying	undiagnosed	persons,	primarily	African	American	baby	boomers,	and	linking	them	to	care.	In	2016	Miller	et	al.	published	a	report	on	the	implementation	of	this	program	and	the	results	from	the	first	year.39	This	study	conducted	routine	HCV	screening	to	identify	previously	undiagnosed,	primarily	African	American	baby	boomers	with	chronic	hepatitis	C	infection	and	link	them	to	care.	To	implement	screening	and	linkage	to	care,	TILT-C	executed	an	electronic	medical	record	prompt,	held	HCV	educational	sessions,	and	used	a	project	coordinator	to	track	testing	outcomes	and	link	HCV+	patients	to	care.	This	multi-faceted	program	yielded	201	HCV	Ab+	patients	(out	of	2,894	tested),	of	which	86.6%	received	HCV	RNA	testing.	Of	those	who	received	an	HCV	RNA	test,	71.3%	were	positive;	98.4%	of	these	patients	were	referred	to	care	and	98.4%	of	those	referred	attended	the	first	appointment.	The	total	linkage	to	care	rate	was	96.8%.	The	CDC	developed	the	Hepatitis	Testing	and	Linkage	to	Care	(HepTLC)	Initiative	as	part	of	the	Viral	Hepatitis	Action	Plan	released	by	HHS.	Between	2012	and	2014,	the	aim	of	
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the	initiative	was	to	improve	screening	and	linkage	to	care	for	those	with	chronic	HCV.	A	total	of	24	programs	in	geographically	diverse	US	cities	conducted	HCV	testing	on	different	populations,	including	PWID.	This	initiative	is	the	first	step	in	developing	a	nationally	coordinated	effort	to	address	viral	hepatitis,	and	several	studies	assessed	the	impact	of	HepTLC	as	a	means	to	inform	future	endeavors.	The	healthcare	facilities	chosen	by	the	CDC	to	provide	testing	included	community	health	centers,	university	hospitals,	health	departments,	primary	care	centers,	and	public	health	clinics.	People	were	tested	at	sites	like	homeless	shelters,	syringe	service	programs,	methadone	clinics,	alcohol	and	drug	treatment	centers,	and	correctional	facilities.		A	study	by	Blackburn	et	al.	reported	findings	from	the	hepTLC	initiative	from	2012-2014,	and	assessed	how	agencies	with	testing	sites	targeting	PWID	can	improve	testing,	diagnosis,	and	treatment	of	HCV	in	this	population.40	The	results	showed	that	at	84	testing	sites	targeting	PWID,	the	total	number	of	people	tested	with	HCV	Ab	was	15,274.	Of	those	tested,	11,159	(73%)	reported	having	injected	drugs	in	their	lifetime,	7,789	(51%)	reported	injected	drugs	in	the	past	12	months,	and	3,495	(23%)	tested	anti-HCV	positive.	Of	those	with	a	positive	HCV	Ab	test,	1,630	(46.6%)	were	tested	for	HCV	RNA.	A	total	of	1,244	(76%)	were	HCV	RNA	positive.	Receiving	both	the	Ab	and	RNA	tests	on	the	same	day	was	associated	with	increased	success:	601	of	2,465	(24%)	anti-HCV+	people	received	an	HCV	RNA	test	when	there	was	not	a	single	testing	event.	Although	a	few	FQHCs	have	reported	how	they	have	implemented	HCV	screening,	testing,	and	linkage	to	care	initiatives,	there	remains	a	need	for	the	evaluation	of	HCV	opt	out	testing	programs.	Current	data	is	most	often	cited	in	large,	national	studies	of	health	departments,	community	health	centers,	and	hospitals.	Data	specifically	from	FQHCs	on	opt	out	testing	is	lacking.	Of	the	published	literature,	the	program	sites	tend	to	be	exclusively	in	urban	cities,	leaving	out	rural	populations	from	the	studies.		Furthermore,	there	is	limited	evidence	about	integrating	a	robust	HCV	screening	program	and	comprehensive	HCV	treatment	into	primary	care.					
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Chapter	III.	Manuscript		Dual	Opt-Out	Testing	for	Human	Immunodeficiency	Virus	(HIV)	and	Hepatitis	C	Virus	(HCV)	in	Primary	Care	Centers:	The	Time	Is	Now		Introduction		 There	are	an	estimated	3.2	million	people	living	in	the	U.S.	that	are	infected	with	hepatitis	C	virus	(HCV).7	About	75%	of	those	affected	are	unaware	of	their	infection.1	Due	to	the	often	symptom-less	nature	and	slow	progression	of	HCV,	those	infected	may	not	be	aware	of	their	infection	until	complications	from	the	disease	have	become	severe	and	available	treatment	options	have	become	limited.	From	2010-2015,	reported	cases	of	acute	HCV	infection	increased	more	than	2.9-fold,	rising	annually	throughout	this	period.2	Mortality	among	HCV-infected	persons-primarily	adults	aged	55-64	years-increased	during	2006-2010.	In	2013,	HCV-associated	deaths	exceeded	the	combined	number	of	deaths	with	60	other	infectious	diseases	as	underlying	causes.	Deaths	due	to	HCV	have	exceeded	deaths	related	to	human	immunodeficiency	virus/acquired	immunodeficiency	syndrome	(HIV/AIDS)	nationally	since	2007.1			 Although	HCV	is	a	considerable	burden	on	the	healthcare	sector,	funding	for	HCV	prevention	and	research	pales	in	comparison	to	funding	for	HIV	efforts,	even	though	an	estimated	20%	of	those	infected	with	HIV	are	co-infected	with	HCV.12	For	those	who	are	co-infected,	the	chance	of	liver-related	morbidity	and	mortality	is	higher,	even	when	the	HIV	infection	is	well	controlled.22	Co-infected	patients	account	for	93%	of	hepatocellular	carcinoma	cases	and	studies	have	reported	a	10-fold	increase	in	mortality	for	these	patients.23		 In	2012,	the	Centers	for	Disease	Control	and	Prevention	(CDC)	revised	HCV	screening	recommendations	to	include	one-time	testing	of	all	baby	boomers	and	screening	for	those	who	are	at	high	risk	for	infection.11	Screening	for	HCV	leads	to	early	diagnosis	and	thus	earlier	access	to	treatment,	more	treatment	options,	prevention	of	the	development	of	HCV-related	complications,	and	higher	linkage-to-care	success	rates.27	Despite	HCV	being	the	most	common	blood-borne	virus	in	the	US	and	the	substantial	scale	and	burden	of	the	disease,	routine	HCV	testing	is	not	uniformly	practiced.7	HCV	screening	rates	are	reported	
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to	be	as	low	as	54%	and	it	is	estimated	that	more	than	60%	of	individuals	who	have	received	a	diagnosis	are	not	engaged	in	care.11,41		 The	existing	literature	is	limited	to	only	a	few	Federally	Qualified	Health	Centers	(FQHCs)	and	the	implementation,	development,	and	evaluation	of	their	HIV	and	HCV	opt	out	testing	programs.	Opt-out	testing	is	done	after	the	patient	is	notified	that	the	test	will	be	performed.	Opt-out	testing	infers	that	a	patient	consents	to	being	tested,	unless	the	patient	specifically	asks	for	the	test	to	not	be	performed.	The	rationale	for	this	type	of	testing	is	that	it	enables	widespread	testing	that	can	identify	infections	earlier,	increase	the	number	of	people	who	do	not	know	they	are	infected,	reduce	stigma	associated	with	HIV	testing,	and	simplify	testing	because	written	consent	is	not	required.	These	clinics	represented	in	the	published	literature	are	in	large,	urban	cities	and	the	results	are	not	generalizable	to	other	locations	and	populations.	This	study	of	the	HIV/HCV	opt-out	program	of	Southside	Medical	Center	(SMC)	adds	to	the	prior	literature	by	reinforcing	the	success	of	routine	opt-out	testing.	Because	SMC	is	an	access	point	for	over	30,000	people	across	rural	and	urban	counties	in	Georgia,	this	study	presents	additional	data	that	has	not	been	thoroughly	studied.		The	aims	of	our	study	were	to	evaluate	the	prevalence	of	HIV	and	HCV	screening	prior	to	and	following	the	implementation	of	a	dual	routine	opt-out	program,	the	linkage	to	care	practices	for	positive	patients,	and	the	demographic	characteristics	of	positive	patients	in	a	southern	FQHC.			Methods	We	conducted	a	retrospective,	cross-sectional	study	using	electronic	health	record	(EHR)	data	from	patients	receiving	care	at	the	Southside	Medical	Center	(SMC)	in	Atlanta,	Georgia.	The	EHR	system	allows	patient-level	data	to	be	extracted	across	all	clinic	sites	from	2012-2017.	Medical	records	created	prior	to	2012	were	not	available	for	this	study.	Approval	from	the	Georgia	State	University	Institutional	Review	Board	was	obtained	prior	to	study	start.		Diagnostic	codes	from	the	9th	and	10th	revisions	of	the	International	Classification	of	Disease,	Clinical	Modification	(ICD-CM)	were	used	to	find	cases.	The	use	of	ICD	9	codes	first	
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began	in	1979,	and	continued	at	SMC	until	September	30,	2015.	The	current	coding	system	is	ICD	10,	which	began	on	October	1,	2015.42	Inclusion	criteria	for	HIV+	patients	were:	13-64	years	of	age,	treatment	at	one	of	the	10	SMC	clinics,	and	a	diagnosis	of	HIV	infection	using	ICD	9	CM	diagnostic	code	042	and	ICD	10	CM	diagnostic	code	B20.	B20	human	immunodeficiency	virus	(HIV)	disease	includes:	acquired	immune	deficiency	syndrome	(AIDS),	AIDS-related	complex	(ARC),	HIV	infection,	symptomatic.	Inclusion	criteria	for	HCV+	patients	were:	18	years	of	age	and	older,	treatment	at	one	of	the	10	SMC,	and	a	diagnosis	of	HCV	using	ICD	9	CM	diagnostic	codes	070.41:	acute	hepatitis	C	with	hepatic	coma,	070.44:	chronic	hepatitis	C	with	hepatic	coma,	070.51:	acute	hepatitis	C	without	mention	of	hepatic	coma,	070.54:	chronic	hepatitis	C	without	mention	of	hepatic	coma,	and	070.7:	unspecified	viral	hepatitis	C,	and	ICD	10	CM	diagnostic	codes	B17.1:	acute	hepatitis	C,	B18.2:	chronic	viral	hepatitis	C,	and	B19.2:	unspecified	viral	hepatitis	C.	Inclusion	criteria	for	co-infected	HIV+/HCV+	patients	were	the	same	as	the	criteria	detailed	above.	The	year	in	which	the	case	was	counted	depended	on	the	earliest	known	date	for	the	secondary	infection.	The	earliest	diagnostic	dates	for	each	of	the	infections	were	counted	in	the	year	in	which	they	occurred,	so	that	a	co-infected	patient	was	counted	3	times:	as	a	case	for	the	year	in	which	an	HIV+	diagnosis	first	occurred,	as	a	case	for	the	year	in	which	an	HCV+	diagnosis	first	occurred,	and	as	a	case	for	the	year	in	which	a	secondary	infection	diagnosis	first	occurred.		Pre-HIV/HCV	opt-out	testing	implementation	was	defined	as	a	positive	HIV	or	HCV	diagnosis	between	June	2012	and	February	2014.	Post-HIV/HCV	opt-out	testing	implementation	was	defined	as	a	positive	HIV	or	HCV	diagnosis	between	March	2014	and	July	2017.	All-tested	refers	to	all	eligible	patients	who	consented	to	being	tested	for	either	HIV	or	HCV.	The	patient-level	demographic	data	that	were	collected	included	date	of	birth,	age,	sex,	race,	and	ethnicity.	The	EHR	data	was	de-identified	and	unduplicated	prior	to	analysis.	Linkage	to	care	was	defined	as	a	patient	attending	an	appointment	with	a	prescribing	provider	within	30	days	of	the	diagnosis.			Results	
Pre-HIV/HCV	opt-out	implementation		
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SMC	conducted	9,906	HIV	tests	prior	to	HIV/HCV	opt-out	testing	implementation.	The	number	of	HCV	tests	conducted	during	the	pre-HIV/HCV	opt-out	testing	implementation	could	not	be	analyzed,	due	to	multiple	software	updates	and	a	lack	of	documentation	of	HCV	during	this	time.			 There	were	68	patients	identified	as	HIV+.	Sixty-six	of	these	patients	were	linked	to	care	(97.05%).	Of	the	68	diagnosed	with	HIV,	95.59%	were	African	American,	98.53%	were	non-Hispanic,	and	62.50%	were	male.	Thirty-seven	percent	of	these	patients	were	aged	41-50,	25%	were	aged	31-40,	25%	were	aged	51-90,	and	12.5%	were	aged	23-30.	There	were	89	patients	identified	as	HCV+.	Of	these	patients,	67.42%	were	black/African	American,	15.73%	were	white,	11.24%	declined	to	answer,	1.12%	were	unknown,	and	4.49%	were	Asian.	The	majority	of	patients	were	non-Hispanic	(97.75%).	53.93%	were	male	and	46.07%	were	female.	The	age	range	of	HCV+	patients	showed	that	most	patients	were	50-59	years	of	age	or	60-60	years	of	age:	33.71%	and	38.31%,	respectively.	There	was	no	information	about	linkage-to-care	nor	data	on	HCV	Ab	total	tested	prior	to	March	2014.		There	were	3	HCV/HIV	co-infected	patients	identified	prior	to	routine	opt-out	testing.	All	3	patients	were	Black/African	American	and	non-Hispanic.	Two	patients	were	male;	1	was	female.	Their	ages	were	35,	63,	and	57	years	old.	Two	of	the	patients	had	a	primary	diagnosis	of	HIV	and	a	secondary	diagnosis	of	HCV.	The	third	patient	was	diagnosed	with	both	on	the	same	day.	All	three	patients	were	linked	to	care	with	a	referral	to	external	organizations.	This	was	due	to	SMC	not	having	an	Infectious	Disease	clinic	at	that	time.			
Post-HIV/HCV	opt-out	implementation	SMC	conducted	38,283	HIV	tests	and	19,308	HCV	tests	after	HIV/HCV	opt-out	testing	implementation.	There	were	232	HIV+	patients	identified	during	this	time	period.	There	was	a	successful	linkage	to	care	rate	of	96.98%.	Of	the	232	patients	diagnosed	with	HIV,	the	majority	were	African	American	(82.33%)	and	non-Hispanic	(93.53%).	Males	comprised	58.19%	of	the	population.	Patients	were	nearly	evenly	distributed	amongst	the	following	age	categories:	51-90	(28.45%),	23-30	(27.59%),	and	31-40	(21.98%).		
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There	were	274	HCV+	patients	identified	during	this	time	period.	Of	these	patients,	52.92%	were	Black/African	American,	94.89%	were	non-Hispanic,	55.84%	were	male,	and	79.71%	were	linked	to	care.	45.99%	were	60-69	years	of	age	and	31.39%	were	50-59	years	old.	The	other	age	groups	were	as	follows:	9.49%	were	40-49	years	of	age,	5.11%	were	30-39	years	of	age,	4.01%	were	18-29	years	of	age,	and	4.01%	were	equal	to	or	older	than	70	years	of	age.		There	were	13	co-infected	patients	identified	during	this	time.	Of	these	patients,	76.9%	were	male,	61.53%	were	Black/African	American,	92.30%	were	non-Hispanic,	and	61.53%	were	in	the	birth	cohort.	Five	patients	(38.46%)	received	both	diagnoses	concurrently.	Four	patients	had	a	primary	diagnosis	of	HCV,	and	four	patients	had	a	primary	diagnosis	of	HIV.		Eleven	patients	were	linked	to	care.			Discussion		The	HIV	and	HCV	patient	populations	remained	consistent	both	before	and	after	implementation	in	regards	to	demographic	distribution.	These	demographics	reflect	the	general	population	of	the	patients	SMC	serves:	non-Hispanic	African	Americans.33	The	age	distribution	of	the	HCV+	patients	at	SMC	matched	the	trends	seen	nationwide	for	patients	belonging	to	the	1945-1965	birth	cohort.		Comparing	the	amount	of	tests	performed	during	the	pre-HIV/HCV	opt	out	testing	period	to	the	post-HIV/HCV	opt	out	testing	period,	shows	a	286%	increase	for	HIV	tests.	The	increase	in	HIV/HCV	testing	may	partly	be	due	to	the	hiring	of	an	Infectious	Disease	specialist	in	2015.	Referrals	to	external	organizations	for	HIV/HCV	positive	patients	may	take	longer,	require	more	work	and	coordination,	and	have	poor	follow	up.	Internal	referrals	to	the	infectious	disease	department	happened	the	same	day	as	the	diagnosis,	which	some	providers	opting	to	personally	call	the	infectious	disease	clinic	to	refer	the	patient.	SMC	has	fully	incorporated	infectious	disease	into	the	primary	care	environment.	An	infectious	disease	specialist	works	alongside	adult	medicine	providers,	pediatricians,	pharmacists,	OBGYNs,	and	counselors.	There	is	an	onsite	lab	at	each	facility	that	allows	patients	to	see	the	provider	and	get	lab	work	done	immediately	after.	This	comprehensive	
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system	simplifies	and	lessens	the	burden	put	on	patients	to	keep	up	with	their	medications,	diagnoses,	lab	work,	and	appointments.		The	linkage	to	care	rates	for	HIV+	and	HCV+	patients	were	higher	than	those	of	other	studies	and	guidelines.	The	national	HIV	linkage	to	care	goal,	set	by	the	federal	government,	is	at	least	85%	of	persons	linked	to	HIV	medical	care	within	30	days	of	diagnosis.43	For	HIV+	patients,	the	percentages	were	>95%	during	both	time	periods.	The	HCV	linkage	to	care	rate	of	the	post-opt	out	period	(79.71%)	was	also	greater	than	those	found	in	similar	studies	by	Coyle	et	al.	(38.7%	and	66.1%).7,12	Several	barriers	were	identified	during	implementation	of	the	testing	program	and	during	analysis	of	the	available	data.	The	lack	of	access	to	digitized	medical	records	prevented	an	in-depth	look	at	the	actual	prevalence	of	HIV	and	HCV	infection	in	the	patient	population	during	the	years	when	paper	records	were	used.	Complete	records	are	needed	to	fully	demonstrate	the	significance	of	routine	opt-out	testing,	and	resources	should	be	allocated	to	improve	and	update	electronic	health	databases.	In	going	forward	with	new	EHR	software,	health	centers	should	make	it	a	priority	that	patient	information	not	be	lost	when	moving	to	a	different	program.		Additionally,	patient	contact	information	should	be	checked	and	updated	at	every	visit	to	guarantee	that	the	most	up-to-date	information	is	available	for	linkage	to	care	efforts.	Making	patients	aware	of	available	transportation,	prescription	assistance	programs,	and	sliding	scale	pay	fees	should	also	be	of	utmost	importance	during	the	initial	visit.	These	changes	require	financial	resources	and	additional	staffing	that	many	may	not	have	access	to.	To	mitigate	this	issue,	FQHCs	could	train	staff	who	work	in	medical	records	to	transition	the	practice	over	to	digital	medical	records.		SMC	was	able	to	successfully	implement	routine	opt-out	testing	thanks	to	considerable	efforts	to	initiate	and	support	an	Infectious	Disease	(ID)	Clinic	within	the	health	center.	Including	a	separate	ID	Clinic	allowed	providers	and	staff	to	give	focused	care	to	HIV	and	HCV	infected	patients	in	a	smaller,	more	individualized	setting.	The	unique	one-stop	shop	method	at	SMC	enables	patients	to	receive	primary	care	from	their	PCP,	and	then	move	to	ID	treatment	with	an	ID	specialist,	then	to	the	pharmacy	for	any	prescription	needs	with	ease.	This	setting	limits	the	amount	of	trips	one	patient	will	need	to	make	for	
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health	care	which	alleviates	stress	and	the	hassle	of	keeping	track	of	several	appointment	dates	and	times.			Limitations	Our	study	had	several	limitations.	First,	the	population	receiving	primary	care	at	SMC	is	primarily	Black/African	American,	low	socioeconomic	status,	and	uninsured	and	underinsured;	thus,	our	results	may	not	be	generalizable	to	other	populations.	Similarly,	SMC	is	a	community	health	center	located	in	Atlanta,	a	highly	populated	city	in	the	southern	US,	and	the	results	shown	here	may	not	apply	to	other	cities	or	types	of	health	services	across	the	country.	Second,	due	to	high	staff	turnover,	there	is	no	way	to	know	if	providers	are	reliably	moving	through	the	opt-out	prompts	with	the	patients.		There	is	a	lag	in	opt-out	training	for	the	newly	on-boarded	staff,	leading	to	inconsistent	offering	of	opt-out	testing.	Third,	due	to	SMC’s	variability	of	being	a	primary	care	facility	for	some	and	a	walk-in	clinic	for	others,	some	patients	testing	positive	may	have	different	primary	care	providers	outside	of	SMC	and	thus	could	have	been	linked	to	care	elsewhere.			Conclusions	Southside	Medical	Center	is	in	a	unique	position	as	a	community	health	program	located	in	Atlanta,	a	highly	populated	southern	city	facing	the	HIV	epidemic.	SMC’s	development	and	implementation	of	routine	dual	HCV/HIV	opt-out	screening	programs	should	serve	as	an	example	to	other	health	centers	looking	to	improve	care	outcomes	for	patients	living	with	and	at	risk	for	HIV	and	HCV,	as	well	as	the	general	population’s	healthcare	as	a	whole.			 	
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